GI-4000
- Generic Name
- GI-4000
- Drug Type
- Biotech
- Background
A vaccine containing a heat-killed recombinant Saccharomyces cerevisiae yeast transfected with mutated forms of Ras, an oncogene frequently found in solid tumors, with potential immunostimulant and antitumor activity.
- Indication
Investigated for use/treatment in pancreatic cancer.
QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors
Phase 1
Withdrawn
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Radiation: Stereotactic Body Radiation Therapy
- First Posted Date
- 2017-05-30
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- ImmunityBio, Inc.
- Registration Number
- NCT03169738
A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
- First Posted Date
- 2011-03-25
- Last Posted Date
- 2016-08-15
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 11
- Registration Number
- NCT01322815
- Locations
- 🇺🇸
Georgetown University, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath